Clinical Advances in the
Treatment of Prostate Cancer:
A Closer Look at the Role of PARP Inhibitors
A continuing medical
education activity sponsored by NAMCP and AAMCN
This webinar series will provide critical updates on the advances in
the management of Prostate Cancer
These are archives of live webinars held between February 12, 2021
to February 17, 2021
If you participated in any of the live webinars, you are not
eligible to claim credit from the archive of that webinar.
By clicking on each of the titles, you will be able to participate
in each part.
It is not required that you participate in all three or in order.
These activities are valid from March 1, 2021 to March 1, 2023
series is supported by educational grants from
AstraZeneca and Merck Sharp & Dohme Corp.
This activity is intended for healthcare professionals practicing in managed
Instructions for CME/NCPD: Complete the pre-test,
listen to the audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name and email
address on the pre-test, evaluation and post-test. If you close your internet
browser without completing the post test, you will have ONE more opportunity to
complete. A score of 70% must be achieved on the post test to receive continuing
education credits. If you do not pass the post test after two attempts, you will
not be eligible to try again. Once you complete the evaluation form and score
70% or higher on your post test, you will automatically be given your
Prostate cancer is the most diagnosed non-cutaneous
cancer in men in the US and remains the second leading cause of cancer deaths
among American men, with an estimated 174,000 new cases diagnosed in 2020.
Prostate cancer deaths are typically the result of castration-resistant prostate
cancer (CRPC), and most patients will eventually experience disease progression
despite castration, with a median duration of response of 12–24 months.
Fortunately for these patients, novel therapies have changed the treatment
paradigm, as recent data has shown that newer options, including PARP
inhibitors, greatly improves outcomes.